| Document |
Document Title |
|
WO/2021/070150A1 |
The present invention relates to an inhalable composition comprising a therapeutically effective dosage amount of compound (I), 2-{4-[(2S)-1,1-difluoro-2-hydroxypropyl]phenyl}-N-{4-[3-(2-e
thylphenyl) pyrazine-2-yl]phenyl}acetamide or a ...
|
|
WO/2021/069721A1 |
Compounds (1-2) as modulators of Activating Transcription Factor 6 (ATF6) are provided. The compounds may find use as therapeutic agents for the treatment of diseases or disorders mediated by ATF6 and may find particular use in the treat...
|
|
WO/2021/070090A1 |
Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formul...
|
|
WO/2021/070957A1 |
Provided are a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, and a medical composition which contains the same and is used to treat or prevent cognitive function diseases or disorders. [In the formula...
|
|
WO/2021/069575A1 |
The present invention relates to novel heteroaryl-substituted pyrazine derivatives of the general formula (I), in which the structural elements R1, R2, R3, R4, R5 and R6 have the meaning given in the description, to formulations and comp...
|
|
WO/2021/068179A1 |
The present invention provides novel heteroaryl-substituted pyrazine derivatives of the general formula (I), in which the structural elements R 1, R 2, R 3, R 4, R 5 and R 6 have the meaning given in the description, formulations and com...
|
|
WO/2021/070132A1 |
Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Such compounds are represented by Formula I as follows: Formula I wherein R1, R2, R3,...
|
|
WO/2021/069701A1 |
Compounds (I) as modulators of Activating Transcription Factor 6 (ATF6) are provided. The compounds may find use as therapeutic agents for the treatment of diseases or disorders mediated by ATF6 and may find particular use in the treatme...
|
|
WO/2021/064677A1 |
Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: Formula I.
|
|
WO/2021/067696A1 |
Disclosed herein are substituted hexahydro-1H-cyclopenta[c]pyrrole compounds, which may be useful as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceu...
|
|
WO/2021/066573A1 |
The present invention pertains to: a novel compound; and a use thereof in treating autoimmune diseases. A pharmaceutical composition for treating or preventing autoimmune diseases containing the novel compound of the present invention ca...
|
|
WO/2021/063856A1 |
The present invention provides novel compounds having the general formula (I) wherein R1 to R6 are as described herein, compositions including the compounds and methods of using the compounds.
|
|
WO/2021/064142A1 |
The present invention relates to a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof : formula (I) and to pharmac...
|
|
WO/2021/063967A1 |
The present invention relates to a compound of the formula (I) wherein Ar represents a phenyl or a 6-membered heteroaryl group, R1 and R2 represent independently a hydrogen atom or a deuterium atom, R3 represents (1) a -COR4 group, (2) a...
|
|
WO/2021/067266A1 |
Disclosed herein are pyrrolidinyl-based compounds, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.
|
|
WO/2021/067827A1 |
The present disclosure provides compounds, such as compounds of Formula I, and compositions that are MCL1 inhibitors.
|
|
WO/2021/063852A1 |
The present invention provides novel compounds having the general formula: wherein R1 to R4, L1, L2 and X are as described herein, compositions including the compounds and methods of using the compounds.
|
|
WO/2021/067801A1 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or prodrug, and/or tautomer, and/or drug combination of the compound) that inhibit (e.g., antagoniz...
|
|
WO/2021/067606A1 |
The present disclosure relates to bifunctional compounds, which find utility as modulators of SMARCA2 or BRM (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand...
|
|
WO/2021/066922A1 |
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present i...
|
|
WO/2021/067654A1 |
Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
|
|
WO/2021/057910A1 |
Disclosed is a peptidylarginine deiminase inhibitor and a use thereof. In particular, the present invention relates to a compound of peptidylarginine deiminase PAD4 inhibitor represented by formula (I) and various subformulas, a pharmace...
|
|
WO/2021/062003A1 |
The present invention provides a pharmaceutical composition comprising a binary conjugate, DC009, which is a conjugate of a thrombolytic peptide (Pro-Ala-Lys) and a tetrahydroisoquinoline compound having two C1-4 alkyl groups via a lysin...
|
|
WO/2021/059136A1 |
Compounds of the general formula (I), or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
|
|
WO/2021/057872A1 |
Disclosed are a compound represented by general formula (I) or a pharmaceutically acceptable salt, stereoisomer, ester, prodrug, solvate and deuterated compound thereof, a composition which comprises the compound represented by general f...
|
|
WO/2021/061665A1 |
The present invention provides polycyclic thiazolidines, imidazolidines, oxazolidines, and related compounds, which are useful as integrin agonist prodrugs. Methods for the treatment of integrin-mediated diseases such as cancer are also ...
|
|
WO/2021/055612A1 |
The invention provides substituted imidazole carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, lysos...
|
|
WO/2021/055744A1 |
Provided herein are compounds having the formula: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, Ar, X1, X2, and ring B have the meanings as provided herein. The provided compounds are useful Poly ADP-...
|
|
WO/2021/055388A1 |
The disclosed technology relates to derivatives of 2,5-dimercapto-1,3,4-thiadiazole.
|
|
WO/2021/053564A1 |
The invention relates to a fixed dose combination of remogliflozin or pharmaceutically acceptable salt or ester thereof and DPP-IV inhibitor or pharmaceutically acceptable salt thereof. In particular, a fixed dose combination of remoglif...
|
|
WO/2021/055591A1 |
The invention provides substituted benzimidazole carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, l...
|
|
WO/2021/052892A1 |
The present invention relates to compounds of formula (I), wherein R1, R2, R3, R4 and R5 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds an...
|
|
WO/2021/055376A1 |
The disclosure herein provides compounds and pharmaceutical compositions for the modulation of IL-17A useful for the treatment of inflammatory conditions, such as psoriasis.
|
|
WO/2021/041458A3 |
An organic compound comprising (I). In this organic compound, W is selected from the group consisting of: S, Se, O, and N-Q; and Q is selected from the group consisting of: a straight-chain or branched carbyl, silyl, or hydrocarbyl, a br...
|
|
WO/2021/047572A1 |
Disclosed in the present invention is a GSK-3β/ChE double inhibitor with a structural formula as shown in formula (I), or a pharmaceutically acceptable salt of formula (I) or a solvate thereof. The small chemical molecules involved in t...
|
|
WO/2021/049840A1 |
The present specification relates to a heterocyclic compound and an organic light-emitting device comprising same.
|
|
WO/2021/050915A1 |
The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods ...
|
|
WO/2021/051034A1 |
Provided herein are RAS protein degraders, e.g., a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a RAS-me...
|
|
WO/2021/049843A1 |
The present specification relates to a compound of chemical formula 1 and an organic light emitting device comprising same.
|
|
WO/2021/050654A1 |
A process for the manufacture N-(5-((5R,6S)-5-amino-6-fluorooxepan-2-yl)-1-methyl-1H-pyraz
ol-4-yl)-2-(2,6-difluorophenyl)thiazole-4-carboxamide (I) is claimed
|
|
WO/2021/048135A1 |
The present invention provides pharmaceutical combinations comprising (a) a compound of formula (I) wherein R represents phenyl or pyridinyl; wherein phenyl is optionally substituted by one or two substituents independently selected from...
|
|
WO/2021/042723A1 |
Disclosed are a glutaminase GLS1 inhibitor containing a triazole structure or a pharmaceutically acceptable salt thereof, a preparation method therefor, and an application thereof. A series of compounds containing a triazole structure of...
|
|
WO/2021/043077A1 |
(I) The present invention relates to a substituted pyrazine compound used as an SHP2 phosphatase inhibitor. Specifically, the present invention relates to the compound of formula (I) or a pharmaceutically acceptable salt, an ester, a ste...
|
|
WO/2021/046194A1 |
The present inventions relates to tryptoline-based benzothi azole compounds and their use as both novel resistance modifying agents, and antibiotics.
|
|
WO/2021/043862A1 |
The present invention relates to novel thioridazine analogue compounds of formula (I): wherein R1 is OCH3 or NH2 , particularly suitable to be used in the treatment of pediatric acute myeloid leukemia harboring the t(6;11)(q27;q23) KMT2A...
|
|
WO/2021/044350A1 |
Aspects of the present application relate to solid forms of Encequidar, its mesylate salt and pharmaceutical compositions thereof. Specific aspects relate to crystalline Form EM4, crystalline Form EM5, crystalline Form EM6 and crystallin...
|
|
WO/2021/038068A1 |
The present invention relates to compounds of Formula (I) wherein Ar1, R1 and R2 are as described in the description, and A is 4,5-dihydroisoxazole-3,5-diyl, imidazolidin-4-one-l,3-diyl, oxazol-2- one-3,5-diyl and oxazolidine-2-one-3,5-d...
|
|
WO/2021/009334A3 |
The present invention relates to herbicidal substituted phenyl-pyridazine-diones and substituted phenyl-pyridazinone derivatives of formula (I), as well as to processes and intermediates used for the preparation of such derivatives. The ...
|
|
WO/2021/041450A1 |
A comonomer comprising: wherein W is selected from the group consisting of: S, Se, O, and N-Q; and Q is selected from the group consisting of: a straight-chain or branched carbyl, silyl, or hydrocarbyl, a branched or cyclic alkyl with 1 ...
|
|
WO/2021/041898A1 |
Disclosed herein are embodiments of a pyrazole compound according to formula (I). Compositions comprising the compound, and a method for making the composition also are disclosed. The composition may comprise a carrier, such as a polymer...
|
